

FOI REF: 25/904

2nd January 2026

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

187.

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

•	Belantamab Mafodotin [Blenrep]	0
•	Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone	3
•	Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone	0
•	Bortezomib [Velcade] ± Dexamethasone	0
•	Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)	0
•	Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	1
•	Carfilzomib [Kyprolis] + Dexamethasone	0
•	Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	1
•	Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	27
•	Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	22

•	Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	0										
•	Daratumumab [Darzalex] monotherapy	6										
•	Elranatamab	10										
•	Idecabtagene vicleucel [Abecma]	0										
•	Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	6										
•	Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)	0										
•	Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)	16										
•	Lenalidomide [Revlimid] + Dexamethasone	0										
•	Lenalidomide [Revlimid] monotherapy	57										
•	Panobinostat + Bortezomib + Dexamethasone	0										
•	Pomalidomide [Imnovid] + Dexamethasone	2										
•	Selinexor + Bortezomib [Velcade] + Dexamethasone	3										
•	Selinexor + Dexamethasone	0										
•	Talquetamab	0										
•	Teclistamab [Tecvayli]	0										
•	Any other systemic anti-cancer therapy [please specify]	33										
	<table><tr><td>Melphalan</td><td>4 patients</td></tr><tr><td>Elotuzumab</td><td>1 patient</td></tr><tr><td>VDT PACE</td><td>2 patients</td></tr><tr><td>Cyclophosphamide</td><td>12 patients</td></tr><tr><td>Thalidomide</td><td>14 patients</td></tr></table>	Melphalan	4 patients	Elotuzumab	1 patient	VDT PACE	2 patients	Cyclophosphamide	12 patients	Thalidomide	14 patients	
Melphalan	4 patients											
Elotuzumab	1 patient											
VDT PACE	2 patients											
Cyclophosphamide	12 patients											
Thalidomide	14 patients											

Q3. In the last 6 months, how many patients have been initiated* on the following regimens?

•	Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
•	Carfilzomib [Kyprolis] + Dexamethasone	0
•	Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	0
•	Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	0
•	Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd)	0
•	Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	9
•	Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	6
•	Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	6
•	Lenalidomide [Revlimid] monotherapy	57
•	Lenalidomide [Revlimid] + Dexamethasone	0
•	Selinexor + Bortezomib [Velcade] + Dexamethasone	0
•	Selinexor + Dexamethasone	0
•	Any other systemic anti-cancer therapy [please specify]	3
	Elotuzumab	1 patient
	Cyclophosphamide	1 patient
	Talquetamab	1 patient

*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation.

Q4. In the last 6 months, how many patients have received the following second-line treatment?

- **Lenalidomide [Revlimid] + Dexamethasone**

0.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net